Jens Bjorheim

Jens Bjorheim

Company: Ultimovacs

Job title: Chief Medical Officer

Seminars:

Boosting Immune Checkpoint Inhibitor Activity in Head and Neck Cancers 11:35 am

Checkpoint inhibitors have shown clinically relevant activity in head and neck cancer Telomerase is expressed in Head and Neck cancer and is a relevant target for an off-the-shelf cancer vaccine A sub-optimal T cell repertoire might be optimized by the expansion of telomerase-specific T cellsRead more

day: Day One

Panel Discussion: Strategic Importance of H&N as Proof-of-Concept Indication for Novel Immunotherapies 10:15 am

Defining head and neck as a go-to indication to enhance drug development decision making under the framework of maximizing resource investment, characterized by benefit-cost ratios (BCRs) Explore the likelihood that a drug is successful in H&N cancer and reduce the risk of failure in phase II and III trials Highlighting novel immunotherapies being tested in…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.